WASHINGTON — Two weeks ago, Dr. Joseph Gulfo ran a panel at the Biotech Showcase in San Francisco titled, “The Trump Administration: What to expect from the FDA.”

He left out one key detail: He may end up running the place.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Gulfo would be a terrific choice. He’s knowledgeable, has long experience in both academic and industry, and has the fire in the belly for reform.

  • What is his position on device approvals and safety? Would he keep the current outdated “one type fits all” system, or move to a framework for Precision Devices, with prescreening patients for immune reactivity to determine if device materials are “right for you” before being installed?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy